English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Thursday, September 15, 2016
Eisai Receives License for New Indication for Anticancer Agent Kisplyx (Lenvatinib Mesylate) for Treatment of Advanced Renal Cell Carcinoma
Wednesday, September 14, 2016
エーザイ、社会的責任投資指数「Dow Jones Sustainability Asia Pacific Index」に4年連続選定
Friday, August 26, 2016
Anticancer Agent "Treakisym for Injection 100 mg" Approved in Japan for Additional Indication of Chronic Lymphocytic Leukemia
エーザイ:抗がん剤「トレアキシン点滴静注用100mg」が日本において慢性リンパ性白血病の効能・効果追加の承認取得
Tuesday, August 23, 2016
Eisai to Launch Chocola BB Mouth Ulcer Repair Shot
エーザイ、口内炎外用剤「チョコラBB 口内炎リペアショット」を発売
Tuesday, August 9, 2016
エーザイ、BACE阻害剤でFDAが臨床第III相試験開始に向け十分なデータが得られたことを確認
Friday, August 5, 2016
エーザイ、中国で抗がん剤「ハラヴェン」の新薬承認申請を受理される
Monday, August 1, 2016
Eisai Presents Results of Additional Analysis of Phase III Study of Anticancer Agent Halaven at 14th JSMO Annual Meeting Plenary Session
Eisai and Mamorio to Jointly Develop "Me-MAMORIO" Tracking Tool to Support People With Dementia Going Out

Copyright © 2023 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575